Projects
Drugs & Driving: integrating epidemiological and experimental data on drug induced driver impairment and crash risk Ghent University
The present research collaboration aims to integrate epidemiological data and experimental data on drug induced driver impairment and crash risk. Epidemiological data on drug induced crash risk or culpability risk has been collected by Prof Verstraete as part of a European research effort (DRUID) and will be provided by Prof Verstraete for additional, explorative analysis. Experimental data on drug effects on driver impairment will be ...
Development of a biorelevant in vitro drug release method for long-acting injectable nanosuspensions of poorly soluble drugs. KU Leuven
Sustained parenteral drug delivery can significantly improve treatment adherence and, hence, the clinical outcome of various chronic illnesses, such as HIV and schizophrenia to name just a few. Long-acting injectable (LAI) nano-/microsuspensions constitute an attractive formulation strategy for poorly soluble drugs and have been the subject of increasing research (Chapter 1). These LAI formulations possess unique features offering ...
CD3 - the Centre for Drug Design and Discovery – discovering new drugs based on innovative research KU Leuven
Het Centre for Drug Design and Discovery (CD3) is een drug discovery centrum en investeringsfonds dat focust op de transformatie van innovatief basisonderzoek naar klinische toepassing. CD3’s activiteiten zijn steeds gebaseerd op een samenwerkingsmodel met academische onderzoeksgroepen en biotech/pharma partners om samen nieuwe geneesmiddelen te ontwikkelen. Het ervaren drug discovery team van CD3 investeert in bedrijven en in vroege drug ...
Drug resistance in MYC/MYCN driven tumor entities as a consequence of replicative stress induced DNA damage response: an entry point for synthetic lethal drugs Ghent University
Chemoresistance is a major impediment to succesful treatment of a growing number of cancer entitites. Circumventing this phenomenon demands highly selective and efficient targeting of cancer-specific pathways. We have recently discovered that MYC(N)-driven tumors show strong upregulation of genes involved in replicative stress-induced DNA damage repair. We thereby identified FOXM 1 as a central regulator. Our data suggest that FOXM1 driven ...
Drug resistance in MYC/MYCN driven tumor entities as a consequence of replicative stress induced DNA damage response : an entry point for synthetic lethal drugs. University of Antwerp
Discourse on Drugs HOGENT
How to reimburse and pay orphan drugs for rare diseases? KU Leuven
Orphan drugs are very expensive drugs that are used to treat rare diseases. Although there are between 5,000 and 7,000 rare diseases affecting a total of 30-40 million patients in Europe, only 151 orphan drugs are available to treat such patients. As a result, market access is an issue of high priority. Of those 151 orphan drugs, only 86 drugs are fully reimbursed by RIZIV/INAMI in Belgium, implying that the patient does not have to pay for ...
Development of a self-emulsifying solid dosage form via co-processing of polyglycolised glyceride/polymer-mixtures with pharmaceutical carriers: enhancement of the bioavailability of poorly water soluble drugs Ghent University
The first aim of this project is to evaluate the potential of polyglycolised glyceride/polymer-mixtures for improving the solubility and bioavailability of itraconazole (used as a model for poorly water soluble drugs). The second aim of this project is to co-process the drug/SEDDS-mixture with a carrier in order to obtain a product (powder, granules) suitable for compression.